Search results
Showing 166 to 180 of 627 results for prescribing
This guideline covers assessing and managing people aged 14 years and over with coexisting severe mental illness (psychosis) and substance misuse. It aims to help healthcare professionals guide people with psychosis with coexisting substance misuse to stabilise, reduce or stop their substance misuse, to improve treatment adherence and outcomes, and to enhance their lives.
We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.
This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.
Frequency of application of topical corticosteroids for atopic eczema (TA81)
Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.
improve clinical and cost effectiveness in relation to the suboptimal prescribing of medicines – for example, between NHS and social...
This guideline covers diagnosing and managing varicose veins in people aged 18 and over. It aims to ensure that people understand the options for treating varicose veins and that healthcare professionals know when to refer people for specialist assessment and treatment.
This quality standard covers care for pregnant women who may be at risk of, or have symptoms and signs of, starting labour and giving birth early (preterm). It describes high-quality care in priority areas for improvement.
View quality statements for QS135Show all sections
Sections for QS135
- Quality statements
- Quality statement 1: Providing information about potential signs and symptoms of preterm labour
- Quality statement 2: Prophylactic vaginal progesterone and prophylactic cervical cerclage
- Quality statement 3: Information for women having a planned preterm birth
- Quality statement 4: Tocolysis for women between 26+0 and 33+6 weeks of pregnancy
- Quality statement 5: Corticosteroids for women between 24+0 and 33+6 weeks of pregnancy
- Quality statement 6: Magnesium sulfate for women between 24+0 and 29+6 weeks of pregnancy
- Update information
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
Renal and ureteric stones: assessment and management (NG118)
This guideline covers assessing and managing renal and ureteric stones. It aims to improve the detection, clearance and prevention of stones, so reducing pain and anxiety, and improving quality of life.
Methadone and buprenorphine for the management of opioid dependence (TA114)
Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.